233 related articles for article (PubMed ID: 35815712)
1. The emerging role of LRRK2 in tauopathies.
Herbst S; Lewis PA; Morris HR
Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
4. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
5. Pathological Functions of LRRK2 in Parkinson's Disease.
Jeong GR; Lee BD
Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
[TBL] [Abstract][Full Text] [Related]
6. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
Sanchez-Contreras M; Heckman MG; Tacik P; Diehl N; Brown PH; Soto-Ortolaza AI; Christopher EA; Walton RL; Ross OA; Golbe LI; Graff-Radford N; Wszolek ZK; Dickson DW; Rademakers R
Mov Disord; 2017 Jan; 32(1):115-123. PubMed ID: 27709685
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.
Lee K; Nguyen KD; Sun C; Liu M; Zafar F; Saetern J; Flierl A; Tetrud JW; Langston JW; Dickson D; Schüle B
J Parkinsons Dis; 2018; 8(1):93-100. PubMed ID: 29480226
[TBL] [Abstract][Full Text] [Related]
9. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
10. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
11. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 at the Crossroad of Aging and Parkinson's Disease.
Hur EM; Lee BD
Genes (Basel); 2021 Mar; 12(4):. PubMed ID: 33805527
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
[TBL] [Abstract][Full Text] [Related]
14. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
Devine MJ; Lewis PA
FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
[TBL] [Abstract][Full Text] [Related]
15. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
Konno T; Siuda J; Wszolek ZK
Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
[TBL] [Abstract][Full Text] [Related]
16. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
18. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases.
Tsafaras G; Baekelandt V
Neurobiol Dis; 2022 Oct; 172():105806. PubMed ID: 35781002
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Henderson MX; Peng C; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]